Adults who are at high risk of becoming infected with the human immunodeficiency virus (HIV), which causes AIDS, were less likely than the general population to be vaccinated against human papillomavirus (HPV), which can cause anal and cervical cancer, according to results presented at the AACR A
Acute flaccid myelitis (AFM) presents significant challenges not only to patients but also to researchers, and efforts must be accelerated to learn more about the condition, experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health,
Until recently, five ebolavirus species were known, with three of these -- Bundibugyo, Sudan and Zaire ebolaviruses -- associated with large human outbreaks.
Infection Control Today is bringing back a much-loved feature, Bug of the Month, which helps educate readers about existing and emerging pathogens of clinical importance in healthcare facilities today.
With the specter of increased resistance to antibiotics, the scientific community is feeling pressure to find new ways to treat bacteria like Group A Streptococcus.
As many as a billion people could be newly exposed to disease-carrying mosquitoes by the end of the century because of global warming, says a new study that examines temperature changes on a monthly basis across the world.
A medicine currently being tested as a chemoprevention agent for multiple types of cancer has more than one trick in its bag when it comes to preventing stomach cancer, Vanderbilt researchers have discovered.
About 40 percent of the global population is at risk for contracting dengue -- the most important mosquito-borne viral infection and a close "cousin" of the Zika virus -- and yet, no effective treatment or safe licensed vaccine exists.
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective.
Researchers from Duke-NUS Medical School, Singapore General Hospital (SGH) and Lion TCR have demonstrated that they were able to engineer HBV-specific T cells, a type of immune cells found in the body, to treat hepatocellular carcinoma (HCC), a commonly occurring liver cancer.